Edwards Melanie A, Hazelrigg Stephen, Naunheim Keith S
Division of Thoracic Surgery, Louisiana State University, 1542 Tulane Avenue, Room 749, New Orleans, LA 70112, USA.
Thorac Surg Clin. 2009 May;19(2):169-85. doi: 10.1016/j.thorsurg.2009.02.007.
Surgery for severe emphysema involves a cohort of patients who are already at risk for increased perioperative morbidity and mortality. Through the careful screening and selection process, improved intraoperative techniques and rigorous attention to postoperative care, the NETT managed to yield acceptable improvements in survival and functional outcomes in this fragile patient cohort and these benefits were sustained over the long-term. Identification of the characteristics associated with a higher risk of death has provided tangible patient selection criteria for the ongoing application of LVRS. Because the NETT was such a large-scale study, the protocols that were developed had to be standardized across several centers. This produced reliable and reproducible standards for evaluation and treatment that can be applied to the surgical treatment of emphysema. When considering these criteria, although individualized patient selection is important, only patients with upper-lobe predominant disease on chest CT and possibly those with non-upper-lobe predominant disease who also have low baseline exercise capacity are appropriate candidates for LVRS. Expectedly, questions remain regarding the exact mechanism whereby the benefits derived from LVRS are obtained. Additionally, the benefit of LVRS in patients with heterogeneous but non-upper-lobe predominant disease remains to be further elucidated. In spite of the limitations of the study, the NETT, through a tremendous coordinated effort, provided valuable outcomes data, answered the pressing questions regarding lung volume reduc-tion surgery that existed at the time, and provided valuable insight into other facets of emphysema physiology and management through direct observation. Based on the NETT findings, in November 2003, CMS published criteria for expanded coverage for LVRS to include non-high-risk patients who demonstrated either upper-lobe predominant emphysema, or non-upper-lobe predominant emphysema and low baseline exercise capacity and who met the screening guidelines.29 This study not only provided data regarding the clinical efficacy of LRVS, but it was instrumental in determining health policy guidelines for the surgical management of emphysema.
重度肺气肿手术涉及一群已经面临围手术期发病率和死亡率增加风险的患者。通过仔细的筛查和选择过程、改进的术中技术以及对术后护理的严格关注,肺减容手术试验(NETT)成功地在这一脆弱患者群体中实现了生存和功能结局的可接受改善,并且这些益处长期持续。识别与较高死亡风险相关的特征为肺减容手术的持续应用提供了切实可行的患者选择标准。由于NETT是一项如此大规模的研究,所制定的方案必须在多个中心进行标准化。这产生了可用于肺气肿外科治疗的可靠且可重复的评估和治疗标准。在考虑这些标准时,虽然个体化患者选择很重要,但只有胸部CT显示上叶为主型疾病的患者以及可能还有非上叶为主型疾病且基线运动能力较低的患者才是肺减容手术的合适候选者。不出所料,关于肺减容手术获得益处的确切机制仍存在问题。此外,肺减容手术在异质性但非上叶为主型疾病患者中的益处仍有待进一步阐明。尽管该研究存在局限性,但NETT通过巨大的协同努力,提供了有价值的结局数据,回答了当时存在的关于肺减容手术的紧迫问题,并通过直接观察为肺气肿生理学和管理的其他方面提供了有价值的见解。基于NETT的研究结果,2003年11月,美国医疗保险和医疗补助服务中心(CMS)发布了扩大肺减容手术覆盖范围的标准,将符合筛查指南的非高危患者纳入其中,这些患者表现为上叶为主型肺气肿或非上叶为主型肺气肿且基线运动能力较低。这项研究不仅提供了关于肺减容手术临床疗效的数据,而且在确定肺气肿外科治疗的卫生政策指南方面发挥了重要作用。